» Articles » PMID: 31125557

Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2019 May 25
PMID 31125557
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Abundant epidemiologic evidence supports an association between idiopathic pulmonary fibrosis (IPF) and lung cancer. Lung tumors in patients with IPF develop preferentially in the periphery immediately adjacent to fibrotic areas, with different histologic distribution and immunohistochemical features compared with non-IPF-associated lung tumors. In this context, evidence indicates that IPF and lung cancer share many pathogenic similarities including genetic and epigenetic markers. It has been suggested that specific germline mutations predispose toward both IPF and lung cancer, leading to imbalance between oncogenes and tumor suppressor genes and ultimately carcinogenesis within fibrotic lungs. Aberrant epigenetic regulation due to methylation, histone modifications, and mainly deregulation of common noncoding RNAs represents a possible pathogenic link between the two disease paradigms. Genetic and epigenetic alterations lead to abnormal activation of common transduction pathways, including Wnt/β-catenin and phosphoinositide 3-kinase/protein kinase B, mediating metaplasia and hyperproliferation in alveolar type II epithelial cells. Cellular transformations in the mesenchymal phenotype represent a common link between lung fibrosis and carcinogenesis. In this review we summarize current data on common cellular and molecular pathogenic mechanisms between IPF and lung cancer and highlight promising therapeutic targets for this disease combination.

Citing Articles

Pingxiao pian attenuate invasiveness and proliferation of lung adenocarcinoma through regulating miR-29b-3p/TGF-β1/Smad/EMT pathway.

Feng J, Chen P, Yuan S, Dai Q, Zheng W, Lin H Discov Oncol. 2025; 16(1):232.

PMID: 39992570 PMC: 11850683. DOI: 10.1007/s12672-025-01959-9.


Evaluating lung cancer risk factors in adults with interstitial lung disease.

Dobkin J, Stanifer B, Salvatore M, Eckhardt C Lung Cancer. 2025; 201:108416.

PMID: 39893773 PMC: 11884992. DOI: 10.1016/j.lungcan.2025.108416.


Impact of antifibrotic therapy on lung cancer incidence and mortality in patients with idiopathic pulmonary fibrosis.

Jo Y, Kim K, Rhee C, Kim Y J Thorac Dis. 2025; 16(12):8528-8537.

PMID: 39831219 PMC: 11740043. DOI: 10.21037/jtd-24-1356.


Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression.

Wang S, Liu G, Yu L, Zhang C, Marcucci F, Jiang Y Transl Lung Cancer Res. 2024; 13(11):3175-3188.

PMID: 39670015 PMC: 11632444. DOI: 10.21037/tlcr-24-811.


Patient-centered care in pulmonary fibrosis: access, anticipate, and act.

Hofman D, Magri T, Moor C, Richeldi L, Wijsenbeek M, Waseda Y Respir Res. 2024; 25(1):395.

PMID: 39487454 PMC: 11531140. DOI: 10.1186/s12931-024-02997-7.